High dose IL-2 in the treatment of metastatic melanoma and metastatic renal cell carcinoma.

被引：0
|
作者：
Woodrum, T [1 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE USA
来源：
ONCOLOGY NURSING FORUM | 2004年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
86
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [21] Dendritic cell vaccine: A potential treatment for metastatic renal cell carcinoma.
    Tanguay, S
    Chagnon, F
    Bergeron, F
    Aprikian, AG
    Gervais, F
    JOURNAL OF UROLOGY, 1998, 159 (05): : 148 - 148
  • [22] IL-15 for the treatment of metastatic malignant melanoma and metastatic renal cell cancer
    Waldmann, Thomas A.
    CYTOKINE, 2010, 52 (1-2) : 68 - 68
  • [23] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2)
    Parikh, Kinjal
    Stenehjem, David D.
    Sendilnathan, Arun
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Grossmann, Kenneth F.
    Wang, Junfeng
    Samlowski, Wolfram E.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [24] First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)
    Ernstoff, M. S.
    Regan, M. M.
    McDermott, D. F.
    Sosman, J. A.
    Dutcher, J. P.
    Clark, J. I.
    Crocenzi, T. S.
    Ochoa, A.
    Atkins, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Rosenbaum, Eli
    Gottfried, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Carducci, Michael Anthony
    Sinibaldi, Victoria J.
    Neiman, Victoria
    Sarid, David
    Gez, Eliahu
    Hayat, Henry
    Peer, Avivit
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Kejzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] Experience with IL-2 in metastatic renal cell carcinoma after treatment with one or more targeted therapies.
    Mai, Hanh P.
    Vu, Peter
    Patel, Arjune
    Clark, Joseph
    Henry, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] TREATMENT OF METASTATIC MELANOMA AND RENAL-CELL CARCINOMA WITH INTERLEUKIN-2
    MANSON, LA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (17): : 1327 - 1327
  • [28] Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC)
    Agarwal, Neeraj
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Crispin, Hilda
    Van Atta, Joan
    Batten, Julia Anne
    Sageser, Daniel
    Samlowski, Wolfram E.
    Grossmann, Kenneth F.
    Wang, Junfeng
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [29] Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.
    Raphael, Jacques
    Thawer, Alia
    Bjarnason, Georg A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [30] Neuropsychiatric side effects of high-dose IL-2 on patient with advanced melanoma or renal cell carcinoma
    Ray, Vani
    Guan, Ran
    Treisman, Jonathan S.
    Nilakantan, Vani
    Chen, Han Yang
    Sinha, Ishan
    Offutt, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345